Free Newsletter
Ranbaxy Labs awaits FDA re-inspection
Free newsletter via e-mail
Tools
Ranbaxy Laboratories said FDA may start inspection of its Dewas, India, plant "any time now," moving the Indian company closer to resuming exports to the world's largest pharmaceutical market from the facility. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: